Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule Cellular Dynamics International (CDI) announced that their two-year collaboration with Roche to substantiate CDI’s iCell® Cardiomyocytes as a predictive tool for assessing the potential cardiotoxic effects of developing drug candidates was completed early and is now transitioning into a standard supply agreement. [Cellular Dynamics International Press Release] Stem Cell Agencies for California and India Sign Agreement to Fund Collaborative Research Projects That Can Accelerate Regenerative Medicine Toward Therapies The California Institute for Regenerative Medicine and the Institute for Stem Cell Biology and Regenerative Medicine have signed a Memorandum of Understanding that outlines ways the two agencies can jointly fund collaborative research projects that bring together top stem cell scientists in California and top stem cell scientists in India. [California Institute for Regenerative Medicine Press Release] CIRM Signs Agreement with France – As the French Debate the Ethics of Stem Cell Science The California Institute for Regenerative Medicine (CIRM) has signed a collaborative agreement on stem cell research with the French Government’s Agence Nationale de la Recherche. [California Institute for Regenerative Medicine Press Release] Cephalon Announces Definitive Agreement to Acquire Gemin X Cephalon, Inc. announced that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. [Cephalon, Inc. Press Release] Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott Seattle Genetics, Inc. announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics’ antibody-drug conjugate technology with antibodies to a single oncology target. [Seattle Genetics, Inc. Press Release] Bellicum Pharmaceuticals Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas Bellicum Pharmaceuticals, Inc. announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas. The award will fund personnel, manufacturing, and clinical testing of Bellicum’s CaspaCIDe™ therapy, which promises to substantially improve outcomes for late stage cancer patients. [Bellicum Pharmaceuticals Press Release] MethylGene Raises $34.5 Million Montreal cancer drug developer MethylGene Inc. is raising $34.5 million in a private placement of shares and warrants that will provide sufficient capital to advance its two primary product candidates to Phase II clinical trials. [Montreal Gazette] UA Wins $11.8 Million NIH Contract to Study Immunity in Elderly The University of Arizona (UA) department of immunobiology and the Arizona Center on Aging have won a five-year, $11.8 million contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), to study declining immunity among the aging. [University of Arizona Press Release] Massachusetts Life Sciences Center Board Approves 2011 Accelerator Program Loans for Early-Stage Companies The Massachusetts Life Sciences Center announced the awarding of $3.75 million in loans to five early-stage life sciences companies. [Massachusetts Life Sciences Center Press Release] ACT to Be Issued Broad Patent for Human ES Cell-Derived RPE Cells in China Advanced Cell Technology, Inc. (ACT) announced that China’s State Intellectual Property Office has allowed the Company’s patent application to provide broad intellectual property protection in China for the manufacturing and pharmaceutical preparations of retinal pigment epithelial (RPE) cells from human embryonic stem (ES) cells. [Advanced Cell Technology, Inc. Press Release] Pluristem to Develop Stem Cell Therapy on Its Own: CEO Pluristem Therapeutics Inc. said it will go solo in developing its stem cell therapy to treat severe obstruction of arteries that can lead to amputation, but will look for a marketing partner to launch the therapy. [Reuters] ReGen Response to FDA 24 Hour Summary of March 23, 2010 Panel Meeting Subsequent to the March 23, 2010 Orthopedic and Rehabilitation Devices Panel meeting to discuss ReGen Biologics, Inc.’s collagen scaffold device, FDA published a 24-hour summary of the panel recommendations. However, FDA’s summary does not accurately reflect the panel’s discussion. [ReGen Biologics, Inc. Press Release] MUSC Spin-Off Receives Two Wound-Healing Patents FirstString Research, Inc., a biotechnology company sprung from a Medical University of South Carolina (MUSC) lab, has received two patents for intellectual property protection for further development and commercialization of its regenerative medicine technology. [PR Newswire] Q&A With Australia-Bound Stem Cell Ace Martin Pera of the University of Southern California announced that he will return to Australia to lead Stem Cells Australia, a new national stem cell consortium. [ScienceInsider] NYU Langone Medical Center Physician Honored by the Israel Cancer Research Fund Daniel F. Roses, MD, the Jules Leonard Whitehill Professor of Surgery and Oncology and chief of the Division of Surgical Oncology at NYU Langone Medical Center was awarded the Tower of Hope Dr. Daniel G. Miller Excellence in Medicine Award by the Israel Cancer Research Fund. [New York University Langone Medical Center Press Release] Ching-Hon Pui, M.D., Recognized with American Association for Cancer Research Award Ching-Hon Pui, M.D., a world renowned leukemia physician and researcher at St. Jude Children’s Research Hospital, is the recipient of the 2011 Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Research from the American Association for Cancer Research. [St. Jude Children’s Research Hospital Press Release] Oxford BioMedica Board Changes Oxford BioMedica plc announced that by mutual agreement, its Chairman, Dr. Alan Kingsman, will leave the Board of Oxford BioMedica at the Company’s forthcoming Annual General Meeting on 5 May 2011. [Oxford Biomedica plc Press Release] Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel Tengion, Inc. announced the addition of two renal research and clinical experts, Ben Humphreys, M.D., Ph.D. and Giuseppe Remuzzi, M.D., F.R.C.P., from the Harvard Stem Cell Institute and Mario Negri Institute respectively, to its panel of Research & Development Advisors. [Tengion, Inc. Press Release] New Stanford Nano Center Provides State-of-the-Art Equipment for Research at the Smallest of Scales The Stanford Nano Center, along with the existing Nanofabrication Facility and Nanocharacterization Laboratory, will upgrade the university’s nanotechnology facilities to rank among the best in the world. [Stanford University Press Release] Two New Basic Science Departments Established The University of Wisconsin School of Medicine and Public Health has created two new basic science departments – the Department of Neuroscience and the Department of Cell and Regenerative Biology. [University of Wisconsin School of Medicine and Public Health Press Release] Cancer Research and the $90 Billion Metaphor Although the “War on Cancer” metaphor has been a target for skeptics, who note that cancer incidence and mortality rates haven’t changed fundamentally, if one sets aside the rhetoric, it’s evident that the cancer campaign has changed therapy and saved lives, as demonstrated in this infographic Science has created of indicators for the seven deadliest cancers. [Science] |